BridgeMD
New treatment option for Bladder (Urothelial, Transitional Cell) Cancer
Official title Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
ClinicalTrials.gov ID: NCT07119996
What this study is testing
What is Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3?
Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3 is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for bladder (urothelial, transitional cell) cancer.
Also referred to as Nicotinic Acid Tablets, Tislelizumab.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- When bladder cancer patients are treated to mobilize their own immune system to fight the tumor, drugs that kill the bacteria can impair the effectiveness of the treatment. The purpose of this study is to find out if the common dietary supplement Vitamin B3 could allow drugs that kill bacteria to not negatively affect treatments that mobilize the immune system to fight tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- The patient voluntarily agrees to participate, is able to provide written informed consent, and is willing and able to comply with the protocol and...
- Aged ≥18 years on the date of signing the informed-consent form (ICF).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix 1).
- Residual tumour after TURBT and histologically confirmed urothelial carcinoma of the bladder staged cT2-T4a N0 M0 by AJCC 8th edition imaging; for...
- An infection occurring from 30 days to 1 day before the first dose of immuno-chemotherapy that, in the judgement of the attending physician, required...
You likely can't join if
- Patients meeting any of the following are ineligible:
- Previous therapy directed against PD-1, PD-L1, PD-L2, CTLA-4 or any other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.
- Systemic anticancer therapy or systemic immunomodulator (e.g. interferon, interleukin-2, TNF) within 28 days before enrolment.
- Prior radiotherapy to the bladder.
- Prior antitumour drug therapy, except:
- ≥12 months since the last dose of systemic chemotherapy before study neoadjuvant therapy;
See the full eligibility criteria
- The patient voluntarily agrees to participate, is able to provide written informed consent, and is willing and able to comply with the protocol and schedule of assessments.
- Aged ≥18 years on the date of signing the informed-consent form (ICF).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix 1).
- Residual tumour after TURBT and histologically confirmed urothelial carcinoma of the bladder staged cT2-T4a N0 M0 by AJCC 8th edition imaging; for mixed-histology tumours, the urothelial component must be predominant...
- An infection occurring from 30 days to 1 day before the first dose of immuno-chemotherapy that, in the judgement of the attending physician, required oral or intravenous bactericidal antibiotics and met any of the...
- Clinical features (e.g. ≥38.3 °C or sustained ≥38 °C for ≥1 h with chills, local pain, dysuria, etc.) plus laboratory evidence (WBC \> 10 × 10⁹/L or \< 4 × 10⁹/L, neutrophilia / neutropenia, markedly elevated CRP)...
- Abnormal urinalysis suggestive of urinary-tract infection (e.g. WBC \> 10/HPF, bacteria seen on high-power field, nitrite positive) with pathogen confirmed by urine culture;
- Infection confirmed by imaging or other microbiological tests (e.g. blood culture, nasopharyngeal swab, sputum culture). Permitted bactericidal antibiotics (oral or IV) include but are not limited to:
- β-lactams (penicillins, cephalosporins, carbapenems);
- Glycopeptides (vancomycin, teicoplanin);
- Quinolones (levofloxacin, ciprofloxacin);
- Aminoglycosides (gentamicin, streptomycin).
- Adequate organ function, documented within ≤14 days before enrolment: a. No growth-factor support ≤14 days before sampling and: i. Absolute neutrophil count ≥1.5 × 10⁹/L; ii. Platelets ≥90 × 10⁹/L; iii. Haemoglobin ≥90...
- Considered cisplatin-eligible by the investigator. Patients deemed cisplatin-ineligible must meet ≥1 of: ECOG \> 1 or Karnofsky 60-70 %; creatinine clearance \< 60 mL/min; NCI-CTCAE v5.0 grade ≥2 hearing loss; NCI-CTCAE...
- Women of child-bearing potential agree to use highly effective contraception during the study and for ≥120 days after the last dose of tislelizumab or chemotherapy (whichever is later) and have a negative urine or serum...
- Patients meeting any of the following are ineligible:
- Previous therapy directed against PD-1, PD-L1, PD-L2, CTLA-4 or any other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.
- Systemic anticancer therapy or systemic immunomodulator (e.g. interferon, interleukin-2, TNF) within 28 days before enrolment.
- Prior radiotherapy to the bladder.
- Prior antitumour drug therapy, except:
- ≥12 months since the last dose of systemic chemotherapy before study neoadjuvant therapy;
- Intravesical chemotherapy or immunotherapy completed ≥1 week before study treatment.
- Major surgery or significant trauma within 28 days before enrolment (vascular-access placement and TURBT are not major surgery).
- Live vaccine within 28 days before enrolment (inactivated seasonal influenza vaccine is permitted; intranasal influenza vaccine is live and prohibited).
- Active autoimmune disease requiring systemic therapy that, in the investigator's opinion, would interfere with study treatment.
- Long-term high-dose corticosteroids or other immunosuppressants that, in the investigator's opinion, would interfere with study treatment.
- Clinically significant abnormalities that could affect treatment, including electrolyte disturbance (K, Na, Ca), hypoalbuminaemia, interstitial lung disease, non-infectious pneumonitis, or other uncontrolled systemic...
- Untreated chronic HBV infection with HBV-DNA ≥500 IU/mL (2,500 copies/mL) or HBsAg carrier status. Patients with inactive HBsAg carriage or stable active HBV on antiviral therapy with HBV-DNA \< 500 IU/mL may enrol...
- Active HCV infection. Patients who are anti-HCV-negative, or anti-HCV-positive but HCV-RNA-negative, may enrol. Anti-HCV-positive patients must have HCV-RNA testing.
- History of immunodeficiency (including HIV positivity or other acquired/congenital immunodeficiencies), or prior allogeneic stem-cell or solid-organ transplantation (Appendix 3).
- Known hypersensitivity to other monoclonal antibodies.
- Known hypersensitivity to any study drug or excipient.
- Unresolved toxicities from prior therapy that have not returned to baseline or stabilised, unless considered by the investigator not to pose a safety risk (e.g. alopecia, neuropathy, certain laboratory abnormalities).
- Any condition (medical or substance abuse) that could impede study-drug administration, confound interpretation of results, or place the patient at high risk of complications.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.